Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avanir submits Neurodex NDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Avanir is requesting a priority review for use of its anti-excitatory therapy Neurodex (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The firm completed a rolling submission of the NDA for the neurological disorder June 29. A priority review designation would make approval possible before year end. Avanir previously estimated the U.S. PBA market at $500 mil.; the firm also indicated it planned to have 70 reps in place for launch (1Pharmaceutical Approvals Monthly September 2004, p. 13). PBA is a symptom complex secondary to multiple neurological conditions including Alzheimer's, Parkinson's, multiple sclerosis and stroke...

You may also be interested in...

Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses

Avanir will meet with FDA "within the next few weeks" to discuss delays in its NDA for Neurodex for treatment of pseudobulbar affect, the firm says

AstraZeneca Adds Avanir Reverse Cholesterol Transport Program To Vascular Pipeline

AstraZeneca and Avanir plan to begin development of reverse cholesterol transport enhancing compounds in late 2005 under a deal worth up to $340 mil., the firms announced July 11

Avanir To File Neurodex NDA For Pseudobulbar Affect By End Of 2004

Avanir could see action on its upcoming Neurodex NDA for the treatment of pseudobulbar affect by mid-2005; the firm plans to submit the application by the end of the year and will request priority review.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts